Equity Research
Our research analysts hold advanced scientific or medical degrees and produce research that is widely read by the most prominent life science institutional investors
For institutional investors who would like access to our research products, please email rfromberg@lifescicapital.com
A Differentiated Model
Our equity research is expert-driven, high quality, and highly informed so that we can raise the visibility of covered companies and educate investors on compelling opportunities
We generate thoroughly researched and insightful "deep dive" analyses that provide value to investors
Expert engagement is at the core of our process and enables us to have informed views on complex topics
Our research is broadly distributed to top institutional investors, companies, and biopharma leadership
Research Snapshot
Our team is highly selective in choosing companies to cover, focusing on innovative science, disruptive clinical data, and capable management teams
>50% with MA/PhD/MD
under coverage
distribution list
90 in person and 42 virtual
Our Areas of Focus
- Therapeutics
Immunology and Inflammation
Abivax, Aclaris Therapeutics, ADARx Pharmaceuticals, Aquestive Therapeutics, Attovia Therapeutics, Celldex, DBV Technologies, Dianthus Therapeutics, Eledon Pharmaceuticals, Eupraxia Pharmaceuticals, Immunovant, InflaRx, Inventiva, MoonLake Immunotherapeutics, Oruka Therapeutics, Spyre Therapeutics, Upstream Bio, Viridian Therapeutics, Yarrow Bioscience
Oncology
Adagene, ALX Oncology, Arcus Biosciences, ArriVent BioPharma, Aura Biosciences, BlossomHill Therapeutics, Candel Therapeutics, Celcuity, CG Oncology, Cogent Biosciences, Compass Therapeutics, Context Therapeutics, Crescent Biopharma, Enliven Therapeutics, Faeth Therapeutics, IDEAYA Biosciences, Immunome, Inhibrx Biosciences, Janux Therapeutics, Kura Oncology, Molecular Partners, Monte Rosa Therapeutics, Obsidian Therapeutics, Olema Pharmaceuticals, OnKure Therapeutics, Parabilis Medicines, Perspective Therapeutics, Protara Therapeutics, Pyxis Oncology, Revolution Medicines, Sutro Biopharma, TScan Therapeutics, Zymeworks
Rare Disease
Amylyx Pharmaceuticals, Contineum Therapeutics, Dyne Therapeutics, Hemab Therapeutics, Immix Biopharma, Inhibikase Therapeutics, IRulya Therapeutics, Larimar Therapeutics, Liquidia, Mereo BioPharma, Neurogene, Palvella Therapeutics, Rocket Pharmaceuticals, Satellos Bioscience, Savara, Sionna Therapeutics, Sol-Gel Technologies
Genetic Medicines
Korro Bio, Prime Medicine, Tenaya Therapeutics
Ophthalmology
Kodiak Sciences, Oculis, Opus Genetics, Surrozen, Tarsus Pharmaceuticals
Nephrology
Eloxx Pharmaceuticals, Jade Biosciences, Maze Therapeutics, Vera Therapeutics
Hematology
Damora Therapeutics, Disc Medicine
CNS
Achieve Life Sciences, Apnimed, Bright Minds Biosciences, Compass Pathways, Definium Therapeutics, Immunic, MapLight Therapeutics, Ovid Therapeutics, Praxis Precision Medicines
Cardiometabolic
Corbus Pharmaceuticals, iBio, Mineralys Therapeutics, Structure Therapeutics, vTv Therapeutics
Cardiopulmonary
Tectonic Therapeutic, Tenax Therapeutics
Endocrinology
Entera Bio, MBX Biosciences
Dermatology
Absci, Veradermics
Key Research Activities
We utilize multiple tools for raising the visibility of our coverage universe and engaging with investors
Frequent, In-Depth Research
Deep-dive initiation reports, thought pieces, expert events, and sector analyses. On average, we issue a note every 1.5 months on all of our covered companies
Investor Events with KOLs
Physician Surveys
Medical Meeting Coverage
Sector Analyses
Thematic pieces dedicated to emerging therapeutic areas of investor interest